ALTO-101 – Discover Pharma

Welcome to Discover Pharma! Today is : March 11, 2026

ALTO-101

Central Nervous System,Clinical Development,Clinical Trials,Drug Development,FDA,Pharmaceuticals and therapeutics,Precision medicine,Research & Development
Alto Neuroscience completes Phase 2 enrollment for ALTO-101 in cognitive impairment associated with schizophrenia
Alto Neuroscience has completed patient enrollment in its Phase 2 [...]

February 13, 2026
Central Nervous System,Clinical Development,Drug Development,Regulatory Affairs
Alto Neuroscience receives FDA Fast Track designation for ALTO-101 to treat cognitive impairment in schizophrenia
Alto Neuroscience has received FDA Fast Track designation for its [...]

October 6, 2025

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK